KX1-004

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:KX1-004 is an Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect. KX1-004 has been used to protect the cochlea from hazardous noise.

Price and Availability

KX1-004, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 406540Name: KX1-004CAS#: 518058-84-9Chemical Formula: C16H13FN2O2Exact Mass: 284.09611Molecular Weight: 284.29Elemental Analysis: C, 67.60; H, 4.61; F, 6.68; N, 9.85; O, 11.26

Synonym:KX1004; KX 1004; KX1-004.

IUPAC/Chemical Name:5-fluoro-N-(3-hydroxybenzyl)-1H-indole-2-carboxamide.

InChi Key:TUIHIKXCMCXXJG-UHFFFAOYSA-N

InChi Code:InChI=1S/C16H13FN2O2/c17-12-4-5-14-11(7-12)8-15(19-14)16(21)18-9-10-2-1-3-13(20)6-10/h1-8,19-20H,9H2,(H,18,21)

SMILES Code:O=C(C(N1)=CC2=C1C=CC(F)=C2)NCC3=CC=CC(O)=C3

Technical Data

Additional Information

References

1: Fetoni AR, Bielefeld EC, Paludetti G, Nicotera T,Henderson D. A putative role of p53 pathway against impulse noiseinduced damage as demonstrated by protection with pifithrin-alpha and aSrc inhibitor. Neurosci Res. 2014 Apr-May;81-82:30-7. doi:10.1016/j.neures.2014.01.006. Epub 2014 Jan 25. PubMed PMID: 24472721.

2: Bielefeld EC, Tanaka C, Chen GD, Coling D, Li M, Henderson D, FetoniAR. An Src-protein tyrosine kinase inhibitor to reduce cisplatinototoxicity while preserving its antitumor effect. Anticancer Drugs.2013 Jan;24(1):43-51. doi: 10.1097/CAD.0b013e32835739fd. PubMed PMID:22828384.

3: Bielefeld EC, Hangauer D, Henderson D. Protection from impulsenoise-induced hearing loss with novel Src-protein tyrosine kinaseinhibitors. Neurosci Res. 2011 Dec;71(4):348-54. doi:10.1016/j.neures.2011.07.1836. Epub 2011 Aug 5. PubMed PMID: 21840347;PubMed Central PMCID: PMC3210387.

4: Bielefeld EC, Wantuck R, Henderson D. Postexposure treatment with aSrc-PTK inhibitor in combination with N-l-acetyl cysteine to reducenoise-induced hearing loss. Noise Health. 2011 Jul-Aug;13(53):292-8. doi:10.4103/1463-1741.82962. PubMed PMID: 21768733.

5: Bielefeld EC, Hynes S, Pryznosch D, Liu J, Coleman JK, Henderson D. Acomparison of the protective effects of systemic administration of apro-glutathione drug and a Src-PTK inhibitor against noise-inducedhearing loss. Noise Health. 2005 Oct-Dec;7(29):24-30. PubMed PMID:17478966.

6: Harris KC, Hu B, Hangauer D, Henderson D. Prevention of noise-inducedhearing loss with Src-PTK inhibitors. Hear Res. 2005 Oct;208(1-2):14-25.Epub 2005 Jun 13. PubMed PMID: 15950415.